Japan
· Delayed Price · Currency is JPY MedRx Statistics
Total Valuation
MedRx has a market cap or net worth of JPY 3.13 billion. The enterprise value is 1.16 billion.
| Market Cap | 3.13B |
| Enterprise Value | 1.16B |
Important Dates
The next estimated earnings date is Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MedRx has 47.50 million shares outstanding. The number of shares has increased by 24.99% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 47.50M |
| Shares Change (YoY) | +24.99% |
| Shares Change (QoQ) | +3.29% |
| Owned by Insiders (%) | 4.02% |
| Owned by Institutions (%) | -2.00% |
| Float | 44.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.20 |
| PB Ratio | 1.45 |
| P/TBV Ratio | 1.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.44 |
| EV / Sales | 4.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.73
| Current Ratio | 19.73 |
| Quick Ratio | 19.25 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -39.40% and return on invested capital (ROIC) is -24.23%.
| Return on Equity (ROE) | -39.40% |
| Return on Assets (ROA) | -22.91% |
| Return on Invested Capital (ROIC) | -24.23% |
| Return on Capital Employed (ROCE) | -36.54% |
| Revenue Per Employee | 11.68M |
| Profits Per Employee | -36.64M |
| Employee Count | 22 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.10% in the last 52 weeks. The beta is 1.02, so MedRx's price volatility has been similar to the market average.
| Beta (5Y) | 1.02 |
| 52-Week Price Change | -43.10% |
| 50-Day Moving Average | 76.34 |
| 200-Day Moving Average | 91.91 |
| Relative Strength Index (RSI) | 45.36 |
| Average Volume (20 Days) | 1,368,060 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MedRx had revenue of JPY 257.00 million and -806.00 million in losses. Loss per share was -18.54.
| Revenue | 257.00M |
| Gross Profit | 257.00M |
| Operating Income | -793.00M |
| Pretax Income | -802.00M |
| Net Income | -806.00M |
| EBITDA | -755.00M |
| EBIT | -793.00M |
| Loss Per Share | -18.54 |
Balance Sheet
The company has 1.98 billion in cash and n/a in debt, giving a net cash position of 1.98 billion or 41.63 per share.
| Cash & Cash Equivalents | 1.98B |
| Total Debt | n/a |
| Net Cash | 1.98B |
| Net Cash Per Share | 41.63 |
| Equity (Book Value) | 2.17B |
| Book Value Per Share | 45.65 |
| Working Capital | 1.97B |
Cash Flow
| Operating Cash Flow | -803.00M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -308.56% |
| Pretax Margin | -312.06% |
| Profit Margin | n/a |
| EBITDA Margin | -293.77% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MedRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.99% |
| Shareholder Yield | -24.99% |
| Earnings Yield | -25.71% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MedRx has an Altman Z-Score of 28.83.
| Altman Z-Score | 28.83 |
| Piotroski F-Score | n/a |